My name is Tarun Chandra, and I've been an Analyst on both the Buyside and Sellside. In addition, I've worked in a Corporate Strategy and Finance role for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for individual investors. Prudent Biotech portfolio is a quantitative-driven systematic investing product. More can be learnt about our Biotechnology portfolio, including Performance and Samples, at the website Prudent Biotech. You may also visit our main website Graycell Advisors for a view of our Investment Approach and all Newsletters with samples.
I'm a tech professional who seeks out stocks with asymmetric risk/reward profiles, primarily in the biotech and tech sectors. I often take medium-term positions in risky contrarian markets with the expectation of large time-averaged gains from these special situations. I'm always looking for an undervalued opportunity, even if it's long term, regardless of market cap. I also follow and comment on commodities and demographics.
I am an Assistant Professor at the Auckland Business School (New Zealand). I earned a Ph.D. from Cass Business School, City University of London. I apply academic research to my investment strategy.
I am an almost 40 year old investor with a long term perspective and a lot of patience. I mainly think about the future when investing in stocks. I do not care about what my selection of stocks will do next year, but what the result will be in 2040 or so. To paraphrase Warren Buffett: "You should only have stocks that you would feel comfortable having if the stock market closes up for 10 years." That means that I look for stocks that combine growth and value. It has been proven that the group of dividend initiators and fastest dividend growers outperforms the markets by far in the long run. So I mainly select stocks from this group, although I also select some non-dividend payers that I believe will grow out to great future value players. Hence: from Growth to Value. I appreciate your comments, because I believe I can still learn a lot from your feedback and I believe in the wisdom of crowds.
I'm the author of six published books, an investor, and a cancer survivor. I got my start thirty-two years ago ghost-writing for a UCLA econ. prof who owned a popular stock-picking newsletter. I have been extensively involved in clinical research (consulted with various medical colleges on new technologies) as well as a speaker in post-doctoral continuing ed in the US, UK, and Canada. Right now, I'm re-editing books for publication and writing articles on Seeking Alpha for others who (like me) enjoy doing extensive investment research and profiting from it.
We are a team of scientists at the Johns Hopkins University School of Medicine combining our expertise in biomedical research to identify undervalued assets within the biotechnology sector, as well as our background in quantitative and data science to generate statistical models for steady income generation.
I am the son of an Army pilot, a former chef and long time trader/market watcher. I currently write analysis and commentary for OptionInvestor.com where you can find me on Monday's and Thursdays, when I write the daily Market Wrap. OptionInvestor.com is a package of newsletters focused on using options to improve returns and increase income.
I take a fundamental approach to technical trading where I keep abreast of economic events while applying them to the charts. My main focus is the SP 500 but I am not limited to that. I currently trade gold, oil, the dollar as well as the indices and stocks.
I have taken a profound interest into demographics and how they are affecting market dynamics. My articles here on SeekingAlpha are the result of years of economy watching and research inspired by such.
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I invest in companies that have stock prices much lower than my analysis of their long term earnings potential suggest is warranted. I look mostly at a 3-5 year time horizon, but when I feel a case is extremely compelling over a 1-2 year time frame I sometimes add long dated options positions to my core holdings of common stocks. With a few stocks I own, I've continuously liked the 3-5 year horizon over a long period, and thus have several positions that date back to 1998.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
Education: BA Economics
Experience: I am a lawyer by trade, but have been studying economics and public companies for more than 20 years. I manage family retirement funds.
Disclosure: My articles and comments are solely my opinion, not an investment recommendation or solicitation, and may not represent the views of my employer(s), associates, or other related parties. No guarantees made to accuracy or completeness. I may be long or short in the companies mentioned, and may change my position at any time for any reason. Please do your own due diligence before making any investment. My opinions on Seeking Alpha contain information from numerous sources including, but not limited, to financial statements and other data. This data may not be correct. I advise you to double check the data and information before making any decision on purchasing or selling shares of the equities mentioned. I make no guarantees or warranties as to the accuracy of data or information used in my opinions.
Investment analyst and private investor. Began as trader and short-seller but changed my style few years ago and so I'm lifetime optimist now (as well as one of my idols André Kostolany) - I’m long only. I only write about stocks that I also own. Everything I write is only my opinion and of course, I could be wrong. Always do your DD. I’m stock picker looking for off-the-radar small or nano-cap mostly with a potential to growth hundreds of percent. I prefer stocks from biotech or alternative energy sector, but this is not a dogma. All my investments are long term, risky and I know that I could lose whole or big part of my initial investment....you should also count with it
I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
Disclosure: I'm not a financial adviser. All articles are my opinion - they are not suggestions to buy or sell any securities. Perform your own due diligence and consult a financial professional before trading.
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces the weekly InsiderInsights Newsletter, and offers institutional strength, real-time insider data and analytics via a subscription Data Module and APIs. He is also principal of Insider Asset Management llc, a registered investment advisor in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading (Dearborn 2001), and has a new book due out with Wiley.
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
Sirius Capital is a Biotech Portfolio Management firm specializing in mid term investments in clinical stage biotech and pharma companies.
Our analysts combine their extensive experience in Pharma and drug development with financial management expertise to yield maximal profit to our clients.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
Hello, my name is Bernardo Teixeira and welcome to my page! I'm currently an undergraduate student of Northeatern University majoring in Finance and Computer Science. My investment focus is majorly in value plays, and sometimes in portfolio strategy and macro trends. Since I'm originally from Brazil and I have lived in China for a few years I have a special passion for emerging market equities and investments outside of the United States. I'm currently following three industries; insurance, semiconductors, and airlines. As always please let me know if you have any comments about my articles!
In order to value a company we usually apply three different types of valuation:
1. Comparable Valuation: If we identify a company has enough comparable companies (usually around 4) and their corporate structures are similar to each other than we would likely value this company through a comparable valuation. In our opinion a comps val is not conclusive enough to know whether a company is being mis-priced by the market, but it provides enough information as to understand which stock of the bunch is the cheapest. Below is one good example of a comparable company and one bad one.
A very good example of a stock which we would rely on a comps val is Delta (DAL). Delta is in an industry which there is little product differentiation and airlines have similar corporate structures. In contrast Microsoft (MSFT) is a company which I probably would not use a comps val, because there is no other company that sells the same exact product line as MSFT.
In our comps valuation we use two different sets of ratios. Equity multiples such as P/E, P/S, P/B and PEG, and Enterprise multiples such as EV/Sales, EV/EBITDA, EV/FCF and EV/ Gross Cash Flow. We try to have all our ratios in a forward looking manner using average analyst expectations whenever possible. We also might eventually exclude ratios from the calculation that are not conclusive enough or that have a high dispersion among players of the industry.
2. Discounted Cash Flow Valuation: After completing our comps val my next step is to run a DCF valuation of the company. Usually our preference for a DCF is to not effectively predict what is going to happen in the future, but instead identify how the market is pricing the stock and stipulate three scenarios assumptions. These scenarios are used to estimate what are different analyst expecting from this company and whether those expectations are realistic or not. The bull case scenario reflects the highest analyst expectation, the base case the average, and the bear case the lowest. We also adjust margins accordingly as to reflect the opinion of analyst. For stocks that have a wide coverage this usually a good measure of the market's view of the company. In general we are only long companies that have a very attractive risk/reward ratio, in which the bull case fairly outstrip the base and the bear case is not significantly negative.
Another assumption we like to make is concerning the discount rates. In our opinion relying on CAPM to calculate the expected rate of returns is a very poor choice. There are many problems with CAPM that are not worth mentioning here. Instead we believe that using a base 8% discount rate subjectively adjusted by it the riskiness of the stock is a better approximation of the discount rate.
3. Return on Invested Capital Valuation: Another type of valuation that we like to use is the ROIC method. I'm still developing a model that can be successfully deployed for Seeking Alpha articles. Once I have it complete I will update our assumptions on our methodology.
Companies that we follow: Ping An (PNGAY), PICC (PPCCY), Copa Holdings (CPA), Cameco (CCJ), Qualcomm (QCOM), Noble Energy (NBL), Delta (DAL), Arotech (ARTX).
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
I have been an individual investor for nearly 25 years. My professional background is in finance and investing owning a Bachelor's degree from Michigan State University. Currently, I focus on retirement and dividend income strategies primarily through the use of funds and ETFs.
If you're interested in learning more about dividend income strategies, retirement and ETF analysis, please consider following me by clicking on the "Follow" button at the top of this page next to my name.
In addition, you can find me on:
Twitter - @david_dierking
LinkedIn - David Dierking
Website - Bull Market Analytics
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector.
I am Chirag Shah. I have a Masters degree in Pharmacy. Pharma and Biotech are my passion. I am an opportunistic investor. Currently I am working with a growing generic drug development company as a pharmaceutical formulation scientist.
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
J. Stephen Castellano founded the investment research and strategy consulting firm Ascendere Associates in 2009, building upon a diversified 20-year career in sell side and buy side equity research. His roles included coverage of the steel industry at PaineWebber and telecom services at Warburg Dillon Read (the predecessors to UBS), where he worked closely with institutional sales people, traders and investment bankers. In addition, he provided analytical support for numerous independent valuation, consulting and investment banking studies, including for mergers, secondary offerings and IPOs.
B.A. in economics and MBA from top 10 business school. I have over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange (www.newyorkshockexchange.com), a youth mentorship program that teaches investment management skills and competitive basketball skills.
After spending a dozen years making a big name for herself as a highly respected investigative reporter in the financial arena, Melissa Davis took a chance on her longtime dream in 2015 by becoming her own boss so that she could pour even more time and energy into uncovering the truth about suspicious public companies by conducting the deepest research of her award-winning career. At that point, Ms. Davis had already established herself as a fearless journalist with an impressive talent for exposing corporate fraud. Most recently, she served as the founding editor of TheStreetSweeper, a financial news website dedicated to warning investors about risky stocks that she essentially built from scratch. Under her leadership, TheStreetSweeper soon earned steady applause from some of the biggest names in the business and continued to flourish for years. Prior to launching that well-known website, Ms. Davis spent seven years on the staff of TheStreet.com -- an even more prominent financial outlet founded by "Mad Money" host Jim Cramer -- where she quickly rose to become one of the leading investigative reporters on a large and impressive editorial team. Already the recipient of numerous awards by the time that TheStreet.com hired her away from the largest newspaper in her home state, Ms. Davis went on to land a national prize for enterprise reporting from the Society of American Business Editors and Writers (SABEW) by the time that her tenure there came to an end. Today, she spends her days (and, when necessary, plenty of late nights) trying to do what she has always done the best even better: revealing the dirty secrets about publicly traded companies that investors desperately need -- and inherently deserve -- to know! (She also smothers her adorable granddaughter -- the other great love of her life -- with plenty of hugs and kisses at every available chance.)